Search results for "clinical trial"

showing 10 items of 1656 documents

Use of Ganoderma lucidum (Ganodermataceae, Basidiomycota) as Radioprotector

2020

For millennia, naturopaths and physicians have used Ganoderma lucidum (reishi mushroom) for its diverse therapeutic properties, as recorded in the oldest Chinese herbal encyclopedia. Indeed, a radioprotective effect has been reported in the isolated components of its extracts. A systematic review and meta-analyses (PRISMA) was conducted in March 2020, searching databases including PubMed, Scopus, Embase, and Google Scholar, along with Clinical Trials. The inclusion criteria were ex vivo, in vitro, and in vivo studies, with full texts in English, conducted to determine the radioprotective benefits of G. lucidum, or reports in which ionizing radiation was used. From a total number of 1109 rec…

0301 basic medicinelcsh:TX341-641Ganoderma lucidumBiology03 medical and health sciences0302 clinical medicineIn vivoradioprotectorGanoderma lucidumMushroomGanodermataceaeNutrition and DieteticsTraditional medicinein vitroBasidiomycotabiology.organism_classificationIn vitroClinical trialin vivo030104 developmental biology030220 oncology & carcinogenesisex vivoreishi mushroomlcsh:Nutrition. Foods and food supplyEx vivoFood ScienceNutrients
researchProduct

Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

2017

urpose Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate. Methods With the aim to shed light on this point, we performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies, and the recommendations of international guidelines. In addition, we performed an extensive search on the Clinical Trial Registries databases worldwide, to gather information on the ongoing clinical trials related to this specific topic. Results We identified eight retrospective published studies, two prospective published studies…

0301 basic medicinemTOR inhibitorsCancer Researchmedicine.medical_specialtyPathologymTOR inhibitorEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Oncology; Cancer ResearchTherapeutic algorithmEverolimus; mTOR inhibitors; neuroendocrine tumours; therapy; antineoplastic agents; everolimus; humans; neuroendocrine tumours; pancreatic neoplasms; oncology; cancer researchEndocrine SyndromeNeuroendocrine tumorsAntineoplastic Agent03 medical and health sciences0302 clinical medicineFirst line therapyNeuroendocrine tumourantineoplastic agentsmedicinehumansIntensive care medicinetherapyEverolimusbusiness.industryPancreatic Neoplasmpancreatic neoplasmsGeneral Medicineeverolimusmedicine.diseaseDiscovery and development of mTOR inhibitorsClinical trialEverolimuNeuroendocrine Tumors030104 developmental biologyOncology030220 oncology & carcinogenesisneuroendocrine tumoursNeuroendocrine TumorbusinessEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic NeoplasmsHumanmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

North African Medicinal Plants Traditionally Used in Cancer Therapy.

2017

Background: Cancer is a major cause of mortality worldwide with increasing numbers by the years. In North Africa, the number of cancer patients is alarming. Also shocking is that a huge number of cancer patients only have access to traditional medicines due to several factors, e.g., economic difficulties. In fact, medicinal plants are widely used for the treatment of several pathologies, including cancer. Truthfully, herbalists and botanists in North African countries prescribe several plants for cancer treatment. Despite the popularity and the potential of medicinal plants for the treatment of cancer, scientific evidence on their anticancer effects are still scarce for most of the describe…

0301 basic medicinemedicine.medical_specialtyAlternative medicineCancer therapyReviewanticancerethnobotanicalScientific evidence03 medical and health sciences0302 clinical medicinemedicinecancerPharmacology (medical)Medicinal plantsPharmacologyTraditional medicinebusiness.industrylcsh:RM1-950Cancerfood and beveragesmedicine.diseaseNorth AfricaClinical trial030104 developmental biologylcsh:Therapeutics. PharmacologyDrug development030220 oncology & carcinogenesisEthnobotanybusinessmedicinal plantsFrontiers in pharmacology
researchProduct

2020

Friedreich’s ataxia is the commonest autosomal recessive ataxia among population of European descent. Despite the huge advances performed in the last decades, a cure still remains elusive. One of the most studied hallmarks of the disease is the increased production of oxidative stress markers in patients and models. This feature has been the motivation to develop treatments that aim to counteract such boost of free radicals and to enhance the production of antioxidant defenses. In this work, we present and critically review those “antioxidant” drugs that went beyond the disease’s models and were approved for its application in clinical trials. The evaluation of these trials highlights some …

0301 basic medicinemedicine.medical_specialtyAtaxiaPhysiologyClinical BiochemistryPopulationEpiphenomenonDiseasemedicine.disease_causeBiochemistryEuropean descent03 medical and health sciences0302 clinical medicinemedicineIn patienteducationIntensive care medicineMolecular Biologyeducation.field_of_studybusiness.industryCell BiologyClinical trial030104 developmental biologymedicine.symptombusiness030217 neurology & neurosurgeryOxidative stressAntioxidants
researchProduct

Alzheimer's disease: Only prevention makes sense

2018

Alzheimer's disease therapeutics is one of the most important endeavours in today's clinical investigation. Over more than 30 years of research, no disease-modifying treatment has been approved by either the FDA or the EMA to treat Alzheimer's disease. Recently, the evidence of pathological alterations in the brain tissue has been gathered showing that the signs of brain damage appear more than 20 years before the onset of Alzheimer's dementia. The major aim of this review is to underpin the idea that in Alzheimer's therapeutics, only prevention makes sense. It is difficult to visualise that would-be patients may be treated with endovenous administration of antibodies for several years to d…

0301 basic medicinemedicine.medical_specialtyClinical BiochemistryBrain damageDiseaseBiochemistryAsymptomaticAntioxidantsMice03 medical and health sciences0302 clinical medicineAlzheimer DiseaseAnimalsHumansVitamin EMedicineDementiaHealthy LifestyleTreatment FailureIntensive care medicinePathologicalNootropic AgentsAgedAged 80 and overClinical Trials as Topicbusiness.industryAntibodies MonoclonalCognitionGeneral MedicineMiddle Agedmedicine.diseaseClinical trialDisease Models Animal030104 developmental biologymedicine.symptombusiness030217 neurology & neurosurgeryMinimal cognitive impairmentEuropean Journal of Clinical Investigation
researchProduct

Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-pe…

2018

// Pierpaolo Correale 1 , Cirino Botta 2 , Nicoletta Staropoli 3 , Valerio Nardone 4 , Pierpaolo Pastina 4 , Cristina Ulivieri 5 , Claudia Gandolfo 6 , Tatiana Cosima Baldari 5 , Stefano Lazzi 7 , Domenico Ciliberto 3 , Rocco Giannicola 1 , Antonella Fioravanti 8 , Antonio Giordano 9 , Silvia Zappavigna 10 , Michele Caraglia 9, 10 , Pierfrancesco Tassone 2, 3, 10 , Luigi Pirtoli 4 , Maria Grazia Cusi 6 and Pierosandro Tagliaferri 3 1 Unit of Medical Oncology, Grand Metropolitan Hospital Bianchi Melacrino Morelli, Reggio-Calabria, Italy 2 Medical Oncology Unit, AUO Mater Domini, Magna Graecia University, Catanzaro, Italy 3 Department of Experimental and Clinical Medicine, Magna Graecia Unive…

0301 basic medicinemedicine.medical_specialtyColorectal cancerThymidylate synthaseK-ra03 medical and health sciences0302 clinical medicineInternal medicineOverall survivalCancer vaccineMedicineIn patientK-rasAntitumor activitybiologybusiness.industryBio-markerUniversity hospitalmedicine.diseasePredictive valueColorectal cancerClinical trial030104 developmental biologyBio-markers; Cancer vaccine; Colorectal cancer; K-ras; Thymidylate synthase; OncologyOncology030220 oncology & carcinogenesisbiology.proteinThymidylate synthaseBio-markersbusinessResearch Paper
researchProduct

What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects

2020

Within the COVID-19 pandemic context, the WHO has proposed a list of medicines to treat patients with severe acute respiratory syndrome (SARS-CoV-2). An analysis of their ocular side effects was performed. Only chloroquine and hydroxychloroquine were found to have an ocular impact in the medium and long-term. Detailed search strategies were performed in EMBASE, MEDLINE, SCOPUS and WOS Core Collection. Additionally, the worldwide ongoing clinical trials including chloroquine or hydroxychloroquine were evaluated, and their proposals of drug administration and exclusion criteria analyzed. In general, high maximum cumulative doses of chloroquine or hydroxychloroquine are being used for a short…

0301 basic medicinemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsCoronavirus disease 2019 (COVID-19)Health PersonnelRetinal pathology / researchSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Context (language use)medicine.disease_causeRetinaAntimalarials03 medical and health sciences0302 clinical medicineRetinal DiseasesChloroquineInternal medicinePandemicmedicineHumansRETINARetina – medical therapiesCoronavirusPharmacologyOphthalmologistsSARS-CoV-2business.industryCOVID-19ChloroquineHydroxychloroquineGeneral MedicineSystemic drug retinal ToxicityTechniques of retinal examinationCOVID-19 Drug TreatmentCoronavirusClinical trialOphthalmology030104 developmental biologyCaregiversMedicina Preventiva y Salud Pública030221 ophthalmology & optometryHuman medicinebusinessHydroxychloroquinemedicine.drugEuropean journal of ophthalmology
researchProduct

Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)

2018

Abstract Background Acid sphingomyelinase deficiency (ASMD), a rare lysosomal storage disease, results from mutations in SMPD1, the gene encoding acid sphingomyelinase (ASM). As a result, sphingomyelin accumulates in multiple organs including spleen, liver, lung, bone marrow, lymph nodes, and in the most severe form, in the CNS and peripheral nerves. Clinical manifestations range from rapidly progressive and fatal infantile neurovisceral disease, to less rapidly progressing chronic neurovisceral and visceral forms that are associated with significant morbidity and shorter life span due to respiratory or liver disease. Objectives To provide a contemporary guide of clinical assessments for di…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismDisease030105 genetics & heredityBiochemistryArticle03 medical and health sciencesLiver disease0302 clinical medicineEndocrinologyQuality of lifeInternal medicineGeneticsmedicineLysosomal storage diseaseHumansEnzyme Replacement TherapyMolecular BiologyMonitoring PhysiologicPatient monitoringClinical Trials as TopicAcid sphingomyelinase deficiencyASMDLungbusiness.industryDisease ManagementEnzyme replacement therapyNiemann-Pick Disease Type Amedicine.diseasePhenotypemedicine.anatomical_structureMutationPractice Guidelines as TopicQuality of LifeBone marrowAcid sphingomyelinasebusinessRisk Reduction Behavior030217 neurology & neurosurgerymedicine.drugMolecular Genetics and Metabolism
researchProduct

Proceedings of the 3rd BEAT-PCD Conference and 4th PCD Training School

2018

Abstract Primary ciliary dyskinesia (PCD) is a chronic suppurative airways disease that is usually recessively inherited and has marked clinical phenotypic heterogeneity. Classic symptoms include neonatal respiratory distress, chronic rhinitis since early childhood, chronic otitis media, recurrent airway infections leading to bronchiectasis, chronic sinusitis, laterality defects with and without congenital heart disease including abnormal situs in approximately 50% of the cases, and male infertility. Lung function deteriorates progressively from childhood throughout life. ‘Better Experimental Approaches to Treat Primary Ciliary Dyskinesia’ (BEAT-PCD) is a network of scientists and clinician…

0301 basic medicinemedicine.medical_specialtyHeart diseaseeducationlcsh:Medicine610 Medicine & healthMeeting ReportGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicinePrimary ciliary dyskinesia360 Social problems & social servicesEpidemiologymedicineotorhinolaryngologic diseasesEarly childhood610 Medicine & healthlcsh:SciencePrimary ciliary dyskinesiaBronchiectasisMultidisciplinarybusiness.industrylcsh:RChronic sinusitisGeneral Medicinemedicine.diseaseChronic respiratory diseaseClinical trial030104 developmental biology030228 respiratory systemFamily medicinelcsh:QbusinessWorking group360 Social problems & social servicesBMC Proceedings
researchProduct

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

2016

// Francesco Perrone 1,* , Gustavo Baldassarre 2,* , Stefano Indraccolo 3,* , Simona Signoriello 4 , Gennaro Chiappetta 1 , Franca Esposito 5 , Gabriella Ferrandina 6 , Renato Franco 1,15 , Delia Mezzanzanica 7 , Maura Sonego 2 , Elisabetta Zulato 3 , Gian F. Zannoni 6 , Vincenzo Canzonieri 2 , Giovanni Scambia 6 , Roberto Sorio 2 , Antonella Savarese 8 , Enrico Breda 9 , Paolo Scollo 10 , Antonella Ferro 11 , Stefano Tamberi 12 , Antonio Febbraro 13 , Donato Natale 14 , Massimo Di Maio 1,16 , Daniela Califano 1 , Giosue  Scognamiglio 1 , Domenica Lorusso 7 , Silvana Canevari 7 , Simona Losito 1 , Ciro Gallo 4,** and Sandro Pignata 1,** 1 Istituto Nazionale per lo Studio e la Cura dei Tumor…

0301 basic medicinemedicine.medical_specialtyLiposomal Doxorubicinovarian cancer; phase 3 clinical trial; predictive factors; pACC; DNA-PKDNA-Activated Protein KinaseDisease-Free Survivalpredictive factorDNA-PK03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerPhase 3 clinical trialAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansDNA-PK; ovarian cancer; pACC; phase 3 clinical trial; predictive factorsGynecologyOvarian NeoplasmsAdvanced ovarian cancerphase 3 clinical trialbusiness.industrySignificant differenceDNA-PK; Ovarian cancer; PACC; Phase 3 clinical trial; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; DNA-Activated Protein Kinase; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Prognosismedicine.diseasePrognosisPredictive valuePACCCarboplatinhumanitiesFirst line treatmentovarian cancer030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemalebusinessOvarian cancerPredictive factorsResearch PaperpACC
researchProduct